구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CD19+22 CAR-T cells |
Overview Company | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | Acute Lymphobkastic Leukemia; B Cell Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | lentiviral cotransduction with vectors encoding our previously described fast-off rate CD1 |
MoA Mechanism | targeting chimeric antigen receptor (CAR) T cells have emerged as a strategy to mitigate antigen escape observed after single antigen |
MoA Biomarker | CD19 and CD22 (CAR19-22), which was well tolerated and associated with high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results.. Multiantigen targeting chimeric antigen receptor (CAR) T cells have emerged as a strategy to mitigate antigen escape observed after single antigen targeting therapy. Our initial experience with a bivalent CD19.22.BBζ CAR T-cell construct in children, adolescents and young adults… |
Toxicology CRS | 10% |
Clinical Safety signal | CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results.. Multiantigen targeting chimeric antigen receptor (CAR) T cells have emerged as a strategy to mitigate antigen escape observed after single antigen targeting therapy. Our initial experience with a bivalent CD19.22.BBζ CAR T-cell construct in children, adolescents and young adults… |
Clinical Selected reported efficacy | ORR 1% |
Clinical Reported ORR | 1% |
Clinical Reported PFS | 2.14 |
Clinical Reported OS | 10.04 |
Clinical Result source | ClinicalTrials.gov NCT03287817 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03287817 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CD19+22 CAR-T cells |
Overview Company | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | Acute Lymphobkastic Leukemia; B Cell Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | lentiviral cotransduction with vectors encoding our previously described fast-off rate CD1 |
MoA Mechanism | targeting chimeric antigen receptor (CAR) T cells have emerged as a strategy to mitigate antigen escape observed after single antigen |
MoA Biomarker | CD19 and CD22 (CAR19-22), which was well tolerated and associated with high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results.. Multiantigen targeting chimeric antigen receptor (CAR) T cells have emerged as a strategy to mitigate antigen escape observed after single antigen targeting therapy. Our initial experience with a bivalent CD19.22.BBζ CAR T-cell construct in children, adolescents and young adults… |
Toxicology CRS | 10% |
Clinical Safety signal | CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results.. Multiantigen targeting chimeric antigen receptor (CAR) T cells have emerged as a strategy to mitigate antigen escape observed after single antigen targeting therapy. Our initial experience with a bivalent CD19.22.BBζ CAR T-cell construct in children, adolescents and young adults… |
Clinical Selected reported efficacy | ORR 1% |
Clinical Reported ORR | 1% |
Clinical Reported PFS | 2.14 |
Clinical Reported OS | 10.04 |
Clinical Result source | ClinicalTrials.gov NCT03287817 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03287817 |
추천 비교
추천 비교